title: [Mutational analysis of EGFR and K-RAS in Chinese patients with non-small cell lung cancer].
abstract: OBJECTIVE
  To investigate gene mutations of the epidermal growth factor receptor (EGFR) and K-RAS in Chinese non-small cell lung cancers (NSCLCs).
  
  
  METHODS
  Mutations of exons 18, 19 and 21 of the EGFR and codons 12, 13 of the K-RAS in 101 NSCLCs were detected by PCR-amplifying and gene sequencing, and the relationship between mutations and clinical characters of NSCLCs and response to gefitinib were analyzed.
  
  
  RESULTS
  Overall, 26 EGFR mutations (25.7%), 3 K-RAS mutations (2.9%) were detected, and EGFR mutation frequencies in adenocarcinomas, nonsmoker and female were found to be high (44.2%, 65.7% and 48.3% respectively). Nine out of 10 gefitinib treated patients with disease control was found with EGFR mutation.
  
  
  CONCLUSIONS
  The data suggest that mutation frequency of EGFR in NSCLCs from Chinese patients is higher than that of western ethnicities, such mutations are well correlated with tumor response to gefitinib, and gefitinib is more fit for Chinese NSCLC patients.
authors.affiliation: Department of Oncology, Third People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 201900 PR China.
authors.forename: Feng
authors.initials: F
authors.lastname: Liu
authors.forename: Bin
authors.initials: B
authors.lastname: Jiang
authors.forename: Sheng-ji
authors.initials: SJ
authors.lastname: Gong
authors.forename: Bao-di
authors.initials: BD
authors.lastname: Yao
authors.forename: Wen-ying
authors.initials: WY
authors.lastname: Zhang
authors.forename: Guan-shan
authors.initials: GS
authors.lastname: Zhu
authors.forename: Zhong-zheng
authors.initials: ZZ
authors.lastname: Zhu
authors.forename: Yu-fang
authors.initials: YF
authors.lastname: Gong
authors.forename: Mei-ling
authors.initials: ML
authors.lastname: Wang
authors.forename: Xiao-hua
authors.initials: XH
authors.lastname: Hu
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000235:genetics*; D004252:DNA Mutational Analysis; D066246:ErbB Receptors / Q000235:genetics*; D005260:Female; D000077156:Gefitinib; D011905:Genes, ras / Q000235:genetics*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D009154:Mutation; D016133:Polymerase Chain Reaction; D011799:Quinazolines / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D011799:Quinazolines; D066246:ErbB Receptors; D000077156:Gefitinib